VANCOUVER - InMed Pharmaceuticals Inc. ('InMed' or the 'Company') (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today confirmed that at its annual general meeting of shareholders held on December 19, 2019 (the 'Meeting'), all directors nominated as listed in the information circular dated November 7, 2019 were elected as directors of the Company for the ensuing year.

InMed filed a report of voting results on SEDAR at www.sedar.com on December 20, 2019.

About InMed

InMed Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

Contact:

Brendan Payne

Tel: +1.604.669.7207

(C) 2020 Electronic News Publishing, source ENP Newswire